Polypeptide With Localisation/Targeting Motif TRIZ Cases

A chimeric receptor polypeptide triggers proteolytic cleavage to express a therapeutic antigen receptor on pathogenic immune cells.

TnpB protein forms ribonucleoprotein complexes to cleave polynucleotides, resolving delivery constraints caused by large Cas9 systems.

Antibodies recognize aberrant Galectin-3 binding epitopes on LAMP1, resolving cross-reactions with healthy tissues in solid tumor therapy.

TOXhi CAR cells express elevated TOX2 protein levels to overcome limited therapeutic efficacy in conventional cancer immunotherapy approaches.

Engineered cells display covalently bound moieties on surface glycans to enhance binding specificity.

Localizing chimeric antigen receptors to lung tissue via DPP4 and DEP1 markers depletes senescent cells while minimizing toxic side effects.

CAR T-cells targeting folate receptor 1 overcome chemotherapy resistance in ovarian and breast cancers.

A targeted prodrug enzyme fusion carrier binds to tumor cells and angiogenic endothelial cells.

Metabolic enhancers redirect glucose oxidation to boost T cell respiratory capacity, solving short-lived survival in adoptive immunotherapy.

Modified Clostridial neurotoxins target sensory neurons to inhibit pain transmission while avoiding motor neuron side effects.

A chimeric antigen receptor with a CD28 transmembrane domain promotes dimerization via its hinge.

A cholic acid linked to a nuclear localization sequence peptide transports therapeutic agents into target cells.

Oil body proteins mediate recombinant protein complexes for flotation purification, eliminating expensive extraction tags and reducing production time.

Parvovirus H-1 modifies the immunosuppressive tumor microenvironment to enable effective CAR-T cell therapy against solid tumors.

Antibody-coated culture vessels maintain CD16 surface expression during proliferation, resolving the trade-off between cell yield and marker stability.

Dual receptor CAR T cells reduce age-associated B cell counts and alleviate autoimmune symptoms.

A universal core promoter drives synthetic transcription factors to enable stable gene expression across diverse eukaryotic organisms.

Codon optimization and specific vector selection produce pure Der f1 protein, eliminating impurities from crude dust mite extracts.

Site-directed mutations in leucine dehydrogenase balance reaction rates for isoleucine and valine, resolving prolonged measurement times.

A fusion protein traverses cellular and mitochondrial membranes to restore enzymatic activity, resolving the barrier preventing enzyme replacement therapy.

TolCAST fuses Cas proteins with transposases to resolve scalability and precision trade-offs in eukaryotic genome engineering.

CPP-modified PNA adjuvants resolve the trade-off between vaccine safety and immune response capability by enabling effective mucosal delivery.

An IL12 fusion protein links p40 and p35 subunits to promote active heterodimer formation.

Inserting a peptide linker at the furin cleavage site enables homotrimeric complex formation, resolving low immunogenicity in current HCMV and EBV vaccines.

Engineered immune cells use a two-receptor system to detect cancer antigens and inhibit activation in normal tissues.

Engineered T cell receptors fuse antibody binding domains via polypeptide linkers to enable simultaneous antigen targeting.

Engineered CD64 chimeric receptors on T cells overcome limited antibody-dependent cellular cytotoxicity by redirecting immune cells to target malignancies.

Voltron voltage indicator uses synthetic Janelia Fluor dyes to boost photon yield and response speed for neuronal imaging.

A single-cell analysis platform integrates time-lapse imaging with genomic sequencing to capture cellular activity data.

Segmented chimeric peptides bind viral coat proteins and disrupt membranes, resolving the trade-off between broad-spectrum antiviral efficacy and crop safety.

Fusing TCF1 to a beta-catenin transactivation domain reduces transgene complexity while enhancing memory differentiation and anti-tumor activity.

Drug-inducible dCpf1-based transcriptional activators enable multiplex and tunable activation of endogenous genes in human cells.

Deleting the unstable N-terminal region of TGF-βRII improves fusion protein stability and expression while maintaining binding affinity to block tumor growth.

Dual-activation checkpoints restrict T regulatory cell activity to inflamed tissues, preventing systemic side effects.

Segmented repeat units and functional linkers resolve the contradiction between binding reliability and editing efficacy in genome regulation.

Ndfip1 fusion polypeptides transport into neurons to regulate PTEN levels, resolving the contradiction between axon regeneration and neuronal survival.

A recombinant vaccinia virus encoding interleukin-7 and interleukin-12 enhances tumor selectivity.

Ex vivo expansion of hematopoietic progenitor cells restores white blood cell counts during neutropenia, reducing infection risk in immunocompromised patients.

A synthetic peptide merges a vesicular stomatitis virus transmembrane sequence with a cell-penetrating peptide to enable cellular uptake.

Reversible reagents control T cell expansion by alternating bound and unbound states, preventing exhaustion and anergy during proliferation.

CAAR T cells target PR3-reactive B cells via extracellular binding domains, reducing autoantibody production in vasculitis.

A fusion protein linking a tumor-targeting binding domain to an inflammatory cytokine directs immune activity toward cancer sites.

A CaRROT optogenetic platform modulates intracellular gene expression via light-induced calcium release and nuclear translocation of a dCas9 fusion construct.

A CD19-specific chimeric antigen receptor uses a 4G7-derived single-chain variable fragment to sustain transduced T cells in an activated state.

Fusion proteins combine mammalian sulfatases with plant lectins to facilitate cellular uptake and lysosomal delivery.

Chimeric fusion protein combines PRRSV ORF5 and ORF6 domains with Pseudomonas exotoxin A translocation sequences to reduce interstitial pneumonitis severity.